September 15, 2021
MSD said on September 14 that it has filed its PD-1 inhibitor Keytruda (pembrolizumab) for an additional indication of postoperative adjuvant therapy for renal cell carcinoma (RCC). The submission is based on data from the global PIII KEYNOTE-564 trial, which...read more